drugset / Trial / NCT07275736
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2027-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNCT19 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |